Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Apr 2008
Multicenter StudyMulticenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department.
Recent data are lacking about the number of patients with angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema who present to the emergency department (ED). Current management of the condition and clinical outcomes also are not known. ⋯ ACEI-induced angioedema accounted for almost one-third of angioedema treated in the ED, although it remains a rare ED presentation. A subgroup of these patients still needs inpatient hospitalization for management of upper airway angioedema.
-
Ann. Allergy Asthma Immunol. · Nov 2006
Randomized Controlled Trial Multicenter StudyEffects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
Mometasone furoate dry powder inhaler (DPI) has been shown to effectively treat asthma in children. ⋯ Both mometasone furoate DPI doses were well tolerated and significantly improved lung function, maintained effective asthma control, and improved quality of life in children with asthma.
-
Ann. Allergy Asthma Immunol. · May 2006
Randomized Controlled Trial Multicenter StudyEfficacy and safety of roflumilast in the treatment of asthma.
The central role of chronic inflammation of the airways in asthma pathogenesis is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, the search continues for potentially safer anti-inflammatory alternatives. Roflumilast is an oral, once-daily phosphodiesterase type 4 inhibitor with anti-inflammatory activity in preclinical models of asthma and chronic obstructive pulmonary disease. ⋯ These results support the emerging role of roflumilast, 500 microg/d, in the treatment of asthma.
-
Ann. Allergy Asthma Immunol. · Aug 2005
Randomized Controlled Trial Multicenter Study Clinical TrialEfficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial.
This randomized study examined the efficacy and safety of levocetirizine in pediatric patients with perennial allergic rhinitis. Health-related quality of life (HRQL) was also investigated, which is particularly relevant in children because of the effects of rhinitis on learning, social activities, and comorbidity. ⋯ The study confirmed the efficacy of levocetirizine in relieving symptoms of perennial allergic rhinitis in children between 6 and 12 years of age. A HRQL benefit greater than placebo was shown. The treatment was well tolerated.
-
Ann. Allergy Asthma Immunol. · Oct 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialFluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Optimal therapy for many patients with persistent asthma requires control of both main components of this disease: inflammation and bronchoconstriction. ⋯ In patients symptomatic while taking short-acting beta2-agonists alone, initial maintenance treatment of the 2 main components of asthma, inflammation and smooth muscle dysfunction, with fluticasone propionate and salmeterol, 100 and 50 microg, administered via the Diskus results in greater improvements in overall asthma control compared with treatment of either component alone.